Mankind Pharma Intrinsic Value
MANKIND Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1090.32 | ₹872.26 - ₹1308.38 | -51.8% | EPS: ₹49.56, Sector P/E: 22x |
| Book Value Method | asset | ₹5653.00 | ₹5087.70 - ₹6218.30 | +150.0% | Book Value/Share: ₹3553.17, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4522.40 | ₹4070.16 - ₹4974.64 | +100.0% | Revenue/Share: ₹3698.54, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹4522.40 | ₹4070.16 - ₹4974.64 | +100.0% | EBITDA: ₹4064.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹5653.00 | ₹4522.40 - ₹6783.60 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹678.36 | ₹610.52 - ₹746.20 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹765.70 | ₹689.13 - ₹842.27 | -66.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹4522.40 | ₹4070.16 - ₹4974.64 | +100.0% | ROE: 14.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹1990.51 | ₹1791.46 - ₹2189.56 | -12.0% | EPS: ₹49.56, BVPS: ₹3553.17 |
Want to compare with current market value? Check MANKIND share price latest .
Valuation Comparison Chart
MANKIND Intrinsic Value Analysis
What is the intrinsic value of MANKIND?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Mankind Pharma (MANKIND) is ₹4522.40 (median value). With the current market price of ₹2261.20, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹678.36 to ₹5653.00, indicating ₹678.36 - ₹5653.00.
Is MANKIND undervalued or overvalued?
Based on our multi-method analysis, Mankind Pharma (MANKIND) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.93 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.91 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 14.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 25.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.55x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Mankind Pharma
Additional stock information and data for MANKIND
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹2,413 Cr | ₹-3,899 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹2,152 Cr | ₹1,112 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹1,813 Cr | ₹1,287 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹920 Cr | ₹236 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹1,137 Cr | ₹526 Cr | Positive Free Cash Flow | 7/10 |